AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11499329 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 143
Study 9629935 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative continuous epidural block combined with patient-controlled analgesia (PCA)
Number of subjects: 45
Study 9629935 — intervention group
Group type: COMPARATOR
Intervention: Control group (suppositories or intramuscular injections of analgesics on request)
Number of subjects: 45
Study 8117016 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drain and one conventional mediastinal drain (Group B)
Number of subjects: 180
Study 8117016 — intervention group
Group type: COMPARATOR
Intervention: Conventional mediastinal drains (Group A)
Number of subjects: 180
Study 3354801 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline 1:200,000
Number of subjects: 40
Study 3354801 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine plain
Number of subjects: 40
Study 15647870 — intervention group
Group type: EXPERIMENTAL
Intervention: magnesium/bisacodyl/picolax
Number of subjects: 176
Study 15647870 — intervention group
Group type: COMPARATOR
Intervention: polyethylene glycol (PEG)/picolax
Number of subjects: 176
Study 31088111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 46
Study 31545663 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim treatment
Number of subjects: 60
Study 31545663 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated observation)
Number of subjects: 60
Study 28146402 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid at 4 days after ACL injury, placebo injection of saline at 2 weeks
Number of subjects: 49
Study 28146402 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid at 2 weeks after ACL injury, placebo at 4 days after ACL injury
Number of subjects: 49
Study 28146402 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid at both time intervals
Number of subjects: 49
Study 28146402 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (saline injections at both time intervals)
Number of subjects: 49
Study 26700291 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH-HF intervention plus usual care
Number of subjects: 216
Study 26700291 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 216
Study 23021708 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs identified in the discovery cohort
Number of subjects: 265
Study 23021708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative SNP score model
Number of subjects: 265
Study 23021708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative SNP risk alleles
Number of subjects: 265
Study 21262998 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg twice daily for 28 days (n=27)
Number of subjects: 56
Study 21262998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=29)
Number of subjects: 56
Study 18647203 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth periodontal debridement
Number of subjects: 25
Study 18647203 — intervention group
Group type: COMPARATOR
Intervention: Quadrant-wise scaling and root planing
Number of subjects: 25
Study 16519625 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 10 mg per day injection intramuscularly or intravenously for 2‐7 days (n = 40)
Number of subjects: 90
Study 16519625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, n = 50)
Number of subjects: 90
Study 16767907 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m2 over 30 minutes intravenously weekly for 7 weeks, followed by 1 week of rest, then weekly for 3 weeks every 4 weeks)
Number of subjects: 138
Study 16767907 — intervention group
Group type: COMPARATOR
Intervention: FLEC (5-fluoruracil 1,000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 infused bolus intra-arterially at three-weekly interval for 3 times)
Number of subjects: 138
Study 16767907 — intervention group
Group type: COMPARATOR
Intervention: FLEC
Number of subjects: 138
Study 16767907 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 138
Study 10930202 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine (15 ml, 0.125%)
Number of subjects: 20
Study 10930202 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epidural catheter)
Number of subjects: 20
Study 9460340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone (80 mg/m2) with cytarabine (3 g/m2 daily for 5 days) and etoposide (150 mg/m2 for 3 days) in patients under 60 with AML.
Number of subjects: 136
Study 9460340 — intervention group
Group type: COMPARATOR
Intervention: High-dose mitoxantrone with cytarabine as a single induction regimen in adults over 60 with untreated AML.
Number of subjects: 136
Study 9460340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone with cytarabine in previously untreated adults with ALL.
Number of subjects: 136
Study 8105072 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (400 mg per kilogram every 28 days)
Number of subjects: 313
Study 8105072 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1% albumin)
Number of subjects: 313
Study 3812048 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment group
Number of subjects: 17
Study 3812048 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 17
Study 28994192 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-diameter implants (NDIs)
Number of subjects: 22
Study 28994192 — intervention group
Group type: COMPARATOR
Intervention: Regular-diameter implants (RDIs)
Number of subjects: 22
Study 27196626 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLL)
Number of subjects: 27
Study 27196626 — intervention group
Group type: COMPARATOR
Intervention: Clinical care only (Control)
Number of subjects: 27
Study 25599119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers And Daughters Exercising for Life (MADE4Life)
Number of subjects: 88
Study 25599119 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 88
Study 23131199 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane foam (PUF)
Number of subjects: 52
Study 23131199 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl acetate (PA)
Number of subjects: 52
Study 20121893 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 16
Study 20121893 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐programme physical activity
Number of subjects: 16
Study 18675269 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a woman (informal contact for approximately 5 min)
Number of subjects: 0
Study 18675269 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a woman
Number of subjects: 0
Study 15885996 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (Group A, n=20)
Number of subjects: 63
Study 15885996 — intervention group
Group type: COMPARATOR
Intervention: Resistance training and callisthenics (Group B, n=22)
Number of subjects: 63
Study 14503059 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaobai Mixture (XBM)
Number of subjects: 74
Study 14503059 — intervention group
Group type: COMPARATOR
Intervention: 8-MOP
Number of subjects: 74
Study 11469290 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml of Depo‐Medrol (40 mg)
Number of subjects: 40
Study 11469290 — intervention group
Group type: COMPARATOR
Intervention: 1.0 ml of sterile saline (control)
Number of subjects: 40
Study 9351634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) high dose: 1,540 microg per day
Number of subjects: 12
Study 9351634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) low and medium doses: < 1,000 microg/d
Number of subjects: 12
Study 9351634 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA)
Number of subjects: 12
Study 9351634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 8259628 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg simethicone
Number of subjects: 10
Study 8259628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3919804 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 45
Study 3919804 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injections
Number of subjects: 45
Study 3919804 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 45
Study 31432695 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib in combination with low-dose cytarabine (LDAC)
Number of subjects: 0
Study 31432695 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDAC)
Number of subjects: 0
Study 29882961 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg microdose of dextromethorphan (DM) administered orally with CYP2D6-dependent drugs
Number of subjects: 39
Study 29882961 — intervention group
Group type: COMPARATOR
Intervention: 2 mg microdose of dextromethorphan (DM) administered orally without CYP2D6-dependent drugs
Number of subjects: 39
Study 26973150 — intervention group
Group type: EXPERIMENTAL
Intervention: Family breakfast frequency
Number of subjects: 827
Study 25168125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antidiabetes agents (OADs)
Number of subjects: 224
Study 25168125 — intervention group
Group type: EXPERIMENTAL
Intervention: OAD plus glargine
Number of subjects: 224
Study 25168125 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal bolus regimen
Number of subjects: 224
Study 25168125 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine alone
Number of subjects: 224
Study 25168125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 224
Study 25168125 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HbA1c change
Number of subjects: 224
Study 25168125 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c <7%
Number of subjects: 224
Study 25168125 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c 7-9%
Number of subjects: 224
Study 25168125 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c >9%
Number of subjects: 224
Study 25168125 — intervention group
Group type: COMPARATOR
Intervention: Admission HbA1c ≤7%
Number of subjects: 224
Study 25168125 — intervention group
Group type: COMPARATOR
Intervention: Admission HbA1c >7%
Number of subjects: 224
Study 23139603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin treatment
Number of subjects: 561
Study 20035387 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation and new drug therapies
Number of subjects: 0
Study 20035387 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted treatment approach
Number of subjects: 0
Study 18565859 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 1376
Study 18565859 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 1376
Study 11313177 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control of radical prostatectomy based on surgical parameters (surgical margins, postoperative PSA, urinary incontinence)
Number of subjects: 232
Study 11313177 — intervention group
Group type: COMPARATOR
Intervention: Number of radical prostatectomies performed per year
Number of subjects: 232
Study 9165189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive mode (IM) with 3 applications within a 2‐week period
Number of subjects: 88
Study 9165189 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly mode (MM) during a 3‐month period
Number of subjects: 88
Study 8427957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone/Doxorubicin (regimen 1)
Number of subjects: 105
Study 8427957 — intervention group
Group type: EXPERIMENTAL
Intervention: Teniposide/Cytarabine (regimen 2)
Number of subjects: 105
Study 8427957 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall event-free survival
Number of subjects: 105
Study 8427957 — intervention group
Group type: EXPERIMENTAL
Intervention: Age less than 10 years at initial diagnosis
Number of subjects: 105
Study 8427957 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell count less than 5,000/microL at relapse
Number of subjects: 105
Study 8427957 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of first remission greater than 54 months
Number of subjects: 105
Study 3618289 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (mean final dose: 3.05 mg)
Number of subjects: 81
Study 3618289 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (mean final dose: 130 mg)
Number of subjects: 81
Study 3618289 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 81
Study 3618289 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 81
Study 29268139 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2
Number of subjects: 75
Study 29268139 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2 plus carboplatin AUC4
Number of subjects: 75
Study 27643602 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE (Small Incision Lenticule Extraction)
Number of subjects: 200
Study 26204994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white-yellowish light therapy for half an hour every morning for 4 weeks
Number of subjects: 98
Study 26204994 — intervention group
Group type: COMPARATOR
Intervention: Dim green light condition (control)
Number of subjects: 98
Study 23569339 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympus V-scope (VS)
Number of subjects: 49
Study 23569339 — intervention group
Group type: COMPARATOR
Intervention: Conventional ERCP
Number of subjects: 49
Study 19891619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review consultations
Number of subjects: 29
Study 18816010 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral treatment (CBT)
Number of subjects: 57
Study 18816010 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment (CBT)
Number of subjects: 57
Study 18816010 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 57
Study 16600235 — intervention group
Group type: EXPERIMENTAL
Intervention: Past oral contraceptive use
Number of subjects: 672
Study 16600235 — intervention group
Group type: COMPARATOR
Intervention: Non-prior users
Number of subjects: 672
Study 12955552 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) 10 mg
Number of subjects: 9
Study 12955552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10811154 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting positions (four randomized positions)
Number of subjects: 0
Study 8822673 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic neuropathic patients
Number of subjects: 19
Study 8822673 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19
Study 1330398 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg administered at 8 AM
Number of subjects: 18
Study 1330398 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg administered at 10 PM
Number of subjects: 18
Study 1330398 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg administered once daily
Number of subjects: 18
Study 31870749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of tranexamic acid (TXA) 1000 mg 10 minutes before surgery
Number of subjects: 72
Study 31870749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plain saline)
Number of subjects: 72
Study 31350908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation (12.8 mmol)
Number of subjects: 0
Study 31350908 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 0
Study 29084397 — intervention group
Group type: EXPERIMENTAL
Intervention: In-centre nocturnal haemodialysis (INHD)
Number of subjects: 25
Study 29084397 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodialysis (control)
Number of subjects: 25
Study 27513234 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (P6 electrical stimulation with grade 3 strength)
Number of subjects: 80
Study 27513234 — intervention group
Group type: COMPARATOR
Intervention: Sham group (inactivated electrodes covered by silicone)
Number of subjects: 80
Study 24717698 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.0025 mg
Number of subjects: 286
Study 24717698 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.0050 mg
Number of subjects: 286
Study 24717698 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.0075 mg
Number of subjects: 286
Study 24717698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 22450972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane alone (single dose)
Number of subjects: 6
Study 22450972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam (single dose)
Number of subjects: 6
Study 22450972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane alone (multiple doses)
Number of subjects: 6
Study 22450972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam (multiple doses)
Number of subjects: 6
Study 19222316 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery condition (imagining positively resolved auditory descriptions)
Number of subjects: 0
Study 19222316 — intervention group
Group type: COMPARATOR
Intervention: Verbal condition (listening to the same events while thinking about their verbal meaning)
Number of subjects: 0
Study 19222316 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery condition
Number of subjects: 0
Study 19222316 — intervention group
Group type: COMPARATOR
Intervention: Verbal conditions aimed to increase or reduce verbal comparisons
Number of subjects: 0
Study 18283076 — intervention group
Group type: COMPARATOR
Intervention: Placebo warfarin dose modification schedules
Number of subjects: 569
Study 18283076 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment arm
Number of subjects: 569
Study 15787083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual lumen catheters (DLCs)
Number of subjects: 473
Study 15787083 — intervention group
Group type: COMPARATOR
Intervention: Triple lumen catheters (TLCs)
Number of subjects: 473
Study 15787083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 473
Study 12592232 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 30
Study 12592232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10226724 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resins
Number of subjects: 73
Study 10226724 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 73
Study 9101948 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic extraperitoneal hernia repair (TEP)
Number of subjects: 224
Study 9101948 — intervention group
Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 224
Study 1854110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine plus triple therapy (2 g/d of tetracycline, 750 mg/d of metronidazole, and 5 or 8 bismuth subsalicylate tablets per day)
Number of subjects: 105
Study 1854110 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine alone (300 mg/d)
Number of subjects: 105
Study 6318304 — intervention group
Group type: EXPERIMENTAL
Intervention: mecillinam
Number of subjects: 74
Study 6318304 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 74
Study 30805706 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT exact®
Number of subjects: 303
Study 30805706 — intervention group
Group type: COMPARATOR
Intervention: RetroArc®
Number of subjects: 303
Study 28355323 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 12
Study 28355323 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy based on reflex stimulation (RPT)
Number of subjects: 12
Study 26914684 — intervention group
Group type: EXPERIMENTAL
Intervention: HILT plus exercise (HILT + EX)
Number of subjects: 60
Study 26914684 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser plus exercise (PL + EX)
Number of subjects: 60
Study 24121806 — intervention group
Group type: EXPERIMENTAL
Intervention: Enclosed silver dressing (Mepilex Ag; Aquacel Ag)
Number of subjects: 0
Study 24121806 — intervention group
Group type: COMPARATOR
Intervention: Topical silver sulfadiazine (SSD)
Number of subjects: 0
Study 22846195 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (2-4 weeks after ATT)
Number of subjects: 150
Study 22846195 — intervention group
Group type: COMPARATOR
Intervention: Delayed ART (8-12 weeks after ATT)
Number of subjects: 150
Study 22846195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 19459762 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog + 300 U of rHuPH20 (11.3 microg/mL)
Number of subjects: 26
Study 19459762 — intervention group
Group type: EXPERIMENTAL
Intervention: Humulin R + 240 U of rHuPH20 (10 microg/mL)
Number of subjects: 26
Study 17353259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine TID (3 times daily)
Number of subjects: 678
Study 17353259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine BID (twice daily)
Number of subjects: 678
Study 17353259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 678
Study 15451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care services usage
Number of subjects: 1537
Study 15451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of home care service use
Number of subjects: 1537
Study 15451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated financial adequacy
Number of subjects: 1537
Study 11394733 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin 10 mg
Number of subjects: 36
Study 11394733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg
Number of subjects: 36
Study 11394733 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release oxybutynin 5 mg
Number of subjects: 36
Study 11394733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36